FX Solutions, SAS. and FX Shoulder, Inc. to Merge into FX

FX Solutions was acquired by Ekkio Capital (Paris, FR)

FX Solutions was founded in 2011 in Viriat, France, and there has always been a vision and passion to grow the portfolio to become a major global competitor. With its start in France, they quickly expanded their market presence throughout Europe.

In 2017, FX Solutions was acquired by Ekkio Capital (Paris, FR). This was the driving force to begin expansion into an extremely competitive US market. FX Shoulder USA was launched as a subsidiary of FX Solutions and quickly grew their footprint in the US Market. With many recent changes and innovations in the US, FX Shoulder has become one of the fastest growing and most innovative companies in its market segment. This was done by staying hyper-focused on shoulder arthroplasty—a market segment that continues to grow at an aggressive pace with constant innovation that allows surgeons even more solutions to care for patients.

“With a complete portfolio and with constant innovation, the time is now to join our two companies as one identity on the global stage,” said, Baptiste Martin, CEO of FX. “This will allow us to streamline our efforts and move as one team with one common goal—to grow our portfolio and market share globally with several key areas of opportunity.”

FX Shoulder USA, Inc. is the direct provider of FX Solutions shoulder replacement devices in the US. FX Solutions will continue to provide the portfolio and sales efforts worldwide (OUS). Both will now be branded as one company [FX] with a US Headquarters in Dallas, and a Global Headquarters in Viriat, France.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.